Abstract
Objective
Children with PTEN hamartoma tumor syndrome (PHTS) are at increased risk for developing thyroid abnormalities, including differentiated thyroid carcinoma (DTC). The Dutch PHTS guideline recommends ultrasound surveillance starting from age 18 years. Since the literature describes PHTS patients who developed DTC before this age, the Dutch PHTS expertise center has initiated annual ultrasound surveillance starting from age 12 years. The purpose of this study was to identify the yield of thyroid ultrasound surveillance using this cut-off.
Methods
A retrospective, single center, cohort study was conducted. Pediatric PHTS patients who received thyroid ultrasound surveillance before age 18 years between 2016-2023 were included. Medical records were reviewed. Primary outcomes included prevalence and time to develop thyroid nodules ≥10 mm, nodular growth, goiter, thyroiditis and DTC. Descriptive statistics and Kaplan-Meier analyses were performed.
Results
Forty-three patients were included. Two (5%) were diagnosed with DTC at ages 12 and 17 years. Both DTCs were identified as minimally invasive follicular carcinoma at stages pT3NxMx and pT1NxMx respectively. A total of 84% were diagnosed with thyroid abnormalities at a median age of 12 (9-18) years. Most common findings were benign, including nodular disease (74%), goiter (30%) and autoimmune thyroiditis (12%). Nodular growth was observed in 14 patients (33%) resulting in (hemi)thyroidectomy in 7 (16%).
Conclusion
Thyroid ultrasound surveillance resulted in the detection of DTC in 2/43 (4.65%) PHTS patients before age 18. These findings support the recommendation to initiate thyroid ultrasound surveillance in children with PHTS from at least age 12, preferably within an expertise center.
Keywords: PTEN hamartoma tumor syndrome, thyroid ultrasound surveillance, differentiated thyroid carcinoma, thyroid nodules, goiter, children, Cowden syndrome
Read the full text
5 sections · 3 figures · 3 tables · 1 supplement · PDF
Create your free account to read the full text.
- Full text with figures and tables
- PDF and supplementary files
- Access on every Galenos journal
One Galenos account works on every Galenos journal site.
References
Abdulkareem IH, Blair M. Phosphatase and tensin homologue deleted on chromosome 10. Niger Med J. 2013;54:79-86.
Baran JA, Tsai SD, Isaza A, Brodeur GM, MacFarland SP, Zelley K, Adams DM, Franco AT, Bauer AJ. The clinical spectrum of PTEN hamartoma tumor syndrome: exploring the value of thyroid surveillance. Horm Res Paediatr. 2020;93:634-642. Epub 2021 Apr 22
Dutch Society Of Clinical Genetics (VKGN). PTEN Hamartoma Tumour Syndrome National Guideline, Version 1.0. Last Accessed Date: 01.01.2015. Available from: https://richtlijnendatabase.nl/gerelateerde_documenten/f/22306/IKNL%20richtlijn%20PTEN%20Hamartoom%20Tumor%20Syndroom.pdf
Tuli G, Munarin J, Mussa A, Carli D, Gastaldi R, Borgia P, Vigone MC, Abbate M, Ferrero GB, De Sanctis L. “Thyroid nodular disease and PTEN mutation in a multicentre series of children with PTEN hamartoma tumor syndrome (PHTS)”. Endocrine. 2021;74:632-637. Epub 2021 Jun 28
Smith JR, Liu E, Church AJ, Asch E, Cherella CE, Srivastava S, Kamihara J, Wassner AJ. Natural history of thyroid disease in children with PTEN hamartoma tumor syndrome. J Clin Endocrinol Metab. 2021;106:1121-1130.
Jonker LA, Lebbink CA, Jongmans MCJ, Nievelstein RAJ, Merks JHM, Nieveen van Dijkum EJM, Links TP, Hoogerbrugge N, van Trotsenburg ASP, van Santen HM. Recommendations on surveillance for differentiated thyroid carcinoma in children with PTEN hamartoma tumor syndrome. Eur Thyroid J. 2020;9:234-242. Epub 2020 Jul 28
Smpokou P, Fox VL, Tan WH. PTEN hamartoma tumour syndrome: early tumour development in children. Arch Dis Child. 2015;100:34-37. Epub 2014 Aug 11
Tischkowitz M, Colas C, Pouwels S, Hoogerbrugge N; PHTS Guideline Development Group; European Reference Network GENTURIS. Cancer Surveillance Guideline for individuals with PTEN hamartoma tumour syndrome. Eur J Hum Genet. 2020;28:1387-1393. Epub 2020 Jun 12
Plitt G, Brewer T, Yehia L, Jin J, Shin J, Eng C. Development and progression of thyroid disease in PTEN hamartoma tumor syndrome: refined surveillance recommendations. Thyroid. 2022;32:1094-1100. Epub 2022 Jul 18
Lebbink CA, Dekker BL, Bocca G, Braat AJAT, Derikx JPM, Dierselhuis MP, de Keizer B, Kruijff S, Kwast ABG, van Nederveen FH, Nieveen van Dijkum EJM, Nievelstein RAJ, Peeters RP, Terwisscha van Scheltinga CEJ, Tissing WJE, van der Tuin K, Vriens MR, Zsiros J, van Trotsenburg ASP, Links TP, van Santen HM. New national recommendations for the treatment of pediatric differentiated thyroid carcinoma in the Netherlands. Eur J Endocrinol. 2020;183:11-18.
Tessler FN, Middleton WD, Grant EG, Hoang JK, Berland LL, Teefey SA, Cronan JJ, Beland MD, Desser TS, Frates MC, Hammers LW, Hamper UM, Langer JE, Reading CC, Scoutt LM, Stavros AT. ACR Thyroid Imaging, Reporting and Data System (TI-RADS): white paper of the ACR TI-RADS Committee. J Am Coll Radiol. 2017;14:587-595. Epub 2017 Apr 2
No authors listed. Recommended normative values for thyroid volume in children aged 6-15 years. World Health Organization & International Council for Control of Iodine Deficiency Disorders. Bull World Health Organ. 1997;75:95-97.
Cibas ES, Ali SZ. The 2017 Bethesda system for reporting thyroid cytopathology. Thyroid. 2017;27:1341-1346.
La Rosa GL, Lupo L, Giuffrida D, Gullo D, Vigneri R, Belfiore A. Levothyroxine and potassium iodide are both effective in treating benign solitary solid cold nodules of the thyroid. Ann Intern Med. 1995;122:1-8.
Drissen MMCM, Vos JR, Netea-Maier RT, Gotthardt M, Hoogerbrugge N. Detection and yield of thyroid cancer surveillance in adults with PTEN hamartoma tumour syndrome. Endocr Relat Cancer. 2023;30:e230009.
Hendricks LAJ, Hoogerbrugge N, Mensenkamp AR, Brunet J, Lleuger-Pujol R, Høberg-Vetti H, Tveit Haavind M, Innella G, Turchetti D, Aretz S, Spier I, Tischkowitz M, Jahn A, Links TP, Olderode-Berends MJW, Blatnik A, Leter EM, Evans DG, Woodward ER, Steinke-Lange V, Anastasiadou VC, Colas C, Villy MC, Benusiglio PR, Gerasimenko A, Barili V, Branchaud M, Houdayer C, Tesi B, Yazicioglu MO, van der Post RS, Schuurs-Hoeijmakers JHM; PTEN Study Group; Vos JR. Cancer risks by sex and variant type in PTEN hamartoma tumor syndrome. J Natl Cancer Inst. 2023;115:93-103.
Ngeow J, Mester J, Rybicki LA, Ni Y, Milas M, Eng C. Incidence and clinical characteristics of thyroid cancer in prospective series of individuals with Cowden and Cowden-like syndrome characterized by germline PTEN, SDH, or KLLN alterations. J Clin Endocrinol Metab. 2011;96:2063-2071. Epub 2011 Sep 28
National Comprehensive Cancer Network (NCCN). NCCN Guidelines Cowden Syndrome/PTEN Hamartoma Tumor Syndrome Management Version 3.2023. Last Accessed Date: 01.01.2023. Available from: https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf
Plamper M, Schreiner F, Gohlke B, Kionke J, Korsch E, Kirkpatrick J, Born M, Aretz S, Woelfle J. Thyroid disease in children and adolescents with PTEN hamartoma tumor syndrome (PHTS). Eur J Pediatr. 2018;177:429-435. Epub 2017 Dec 22
Plamper M, Gohlke B, Woelfle J. PTEN hamartoma tumor syndrome in childhood and adolescence-a comprehensive review and presentation of the German pediatric guideline. Mol Cell Pediatr. 2022;9:3.
Brodeur GM, Nichols KE, Plon SE, Schiffman JD, Malkin D. Pediatric cancer predisposition and surveillance: an overview, and a tribute to Alfred G. Knudson Jr. Clin Cancer Res. 2017;23:1-5.
Szabo Yamashita T, Baky FJ, McKenzie TJ, Thompson GB, Farley DR, Lyden ML, Dy BM. Occurrence and natural history of thyroid cancer in patients with Cowden syndrome. Eur Thyroid J. 2020;9:243-246. Epub 2020 Mar 12
Hall JE, Abdollahian DJ, Sinard RJ. Thyroid disease associated with Cowden syndrome: a meta-analysis. Head Neck. 2013;35:1189-1194. Epub 2012 Mar 20
Li H, Li J. Thyroid disorders in women. Minerva Med. 2015;106:109-114.
Tunbridge WM, Evered DC, Hall R, Appleton D, Brewis M, Clark F, Evans JG, Young E, Bird T, Smith PA. The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinol (Oxf). 1977;7:481-493.
Derwahl M, Nicula D. Estrogen and its role in thyroid cancer. Endocr Relat Cancer. 2014;21:273-283. Epub 2014 Jul 22
Clement SC, Kremer LCM, Verburg FA, Simmons JH, Goldfarb M, Peeters RP, Alexander EK, Bardi E, Brignardello E, Constine LS, Dinauer CA, Drozd VM, Felicetti F, Frey E, Heinzel A, van den Heuvel-Eibrink MM, Huang SA, Links TP, Lorenz K, Mulder RL, Neggers SJ, Nieveen van Dijkum EJM, Oeffinger KC, van Rijn RR, Rivkees SA, Ronckers CM, Schneider AB, Skinner R, Wasserman JD, Wynn T, Hudson MM, Nathan PC, van Santen HM. Balancing the benefits and harms of thyroid cancer surveillance in survivors of childhood, adolescent and young adult cancer: Recommendations from the international Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCareSurFup Consortium. Cancer Treat Rev. 2018;63:28-39. Epub 2017 Nov 14
Clement SC, Kremer LC, Links TP, Mulder RL, Ronckers CM, van Eck-Smit BL, van Rijn RR, van der Pal HJ, Tissing WJ, Janssens GO, van den Heuvel-Eibrink MM, Neggers SJ, van Dijkum EJ, Peeters RP, van Santen HM. Is outcome of differentiated thyroid carcinoma influenced by tumor stage at diagnosis? Cancer Treat Rev. 2015;41:9-16. Epub 2014 Nov 11
Francis GL, Waguespack SG, Bauer AJ, Angelos P, Benvenga S, Cerutti JM, Dinauer CA, Hamilton J, Hay ID, Luster M, Parisi MT, Rachmiel M, Thompson GB, Yamashita S; American Thyroid Association Guidelines Task Force. Management guidelines for children with thyroid nodules and differentiated thyroid cancer. Thyroid. 2015;25:716-759.
Tan MH, Mester JL, Ngeow J, Rybicki LA, Orloff MS, Eng C. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res. 2012;18:400-407.
Schultz KAP, Rednam SP, Kamihara J, Doros L, Achatz MI, Wasserman JD, Diller LR, Brugières L, Druker H, Schneider KA, McGee RB, Foulkes WD. PTEN, DICER1, FH, and their associated tumor susceptibility syndromes: clinical features, genetics, and surveillance recommendations in childhood. Clin Cancer Res. 2017;23:76-82.
